| Kurse | Charts | Tools | Aktion |
|---|---|---|---|
| Snapshot | Chart (gross) | Termsheet | Portfolio |
| Times + Sales | Watchlist | ||
| Börsenplätze | |||
| Historisch |
Charts
Tools
Views/derivatives/LatestQuote.cshtml
![Tracker-Zertifikat auf BioSciences h CHF Basket von Zürcher Kantonalbank Chart]( "Tracker-Zertifikate Chart")
Wichtige Stammdaten und Kennzahlen
| Kennzahl | Wert | Kennzahl | Wert |
|---|---|---|---|
| Ratio | 1.00 | Spread | 0.01 % |
| Liquiditätsrating | 6 |
Letzter gehandelter Kurs des Produkts
| 89.727 CHF | -8.702 CHF | -8.84 % |
|---|
| Kurszeit | 09:48:03 | Kursdatum | 26.02.2021 |
| Eröffnung | 0.000 | Vortag | 89.727 |
| Tagestief | 0.000 | Tageshoch | 0.000 |
| 52 W. Tief | 0.000 | 52 W. Hoch | 0.000 |
| Volumen (Stück) | 0 | Börse | SIX Structured Products |
Chart - 1 Jahr
Module werden z.T. nicht angezeigt
SIX Structured Products - Trade Ticker
| Zeit | Symbol | Kurs | Volumen |
|---|---|---|---|
| 09:16:44 | GAMBLU | 0.010 | 100'000 |
| 09:16:41 | ABQUAU | 0.383 | 8'000 |
| 09:16:39 | MDAAYV | 1.330 | 10'000 |
| 09:16:39 | ODAA3V | 0.400 | 7'000 |
| 09:16:39 | ODAA3V | 0.400 | 10'000 |
| 09:16:37 | ODAAQV | 2.320 | 3'333 |
| 09:16:36 | MUSCM | 0.690 | 1'500 |
| 09:16:31 | NEWDTQ | 120.240 | 10 |
| 09:16:30 | OGDAYU | 2.460 | 1'200 |
Stammdaten
| Name | Tracker Certificate* |
| Symbol | MGBIOZ |
| Valor | 56679913 |
| ISIN | CH0566799133 |
| Art | Tracker Certificate |
| Typ | Bull |
| Ausübungsstil | American |
| Emissionstag | 11.02.2021 |
| Währung | CHF |
| Währungssicherheit | Nein |
| COSI Produkt? | Nein |
| Handelsplatz | SIX |
| Emittent | Zürcher Kantonalbank |
Anzeige
Inside
Basiswerte
| Name | ISIN |
|---|---|
| Intuitive Surgical Inc. | US46120E6023 |
| Abiomed Inc. | US0036541003 |
| DexCom Inc. | US2521311074 |
| Thermo Fisher Scientific Inc. | US8835561023 |
| Illumina Inc. | US4523271090 |
| Charles River Laboratories Intl. Inc. | US1598641074 |
| Syneos Health Inc. | US87166B1026 |
| Regeneron Pharmaceuticals Inc. | US75886F1075 |
| Quintiles Transnational Hldg. Inc. | US46266C1053 |
| PRA Health Sciences Inc. | US69354M1080 |
| Insulet Corp. | US45784P1012 |
| Guardant Health Inc. | US40131M1099 |
| Zai Lab Ltd. | US98887Q1040 |
| Veracyte Inc. | US92337F1075 |
| Nanostring Technologies Inc. | US63009R1095 |
| EXACT Sciences Corp. | US30063P1057 |
| Globus Medical Inc. | US3795772082 |
| Teladoc Inc. | US87918A1051 |
| Beigene Ltd. | US07725L1026 |
| Pacific Biosciences of California Inc. | US69404D1081 |
| Twist Bioscience Corp. | US90184D1000 |
| INARI Medical Inc. | US45332Y1091 |
| Arcturus Therapeutics Hlgd INC | US03969T1097 |
| Allakos Inc. | US01671P1003 |
| ARCUS BIOSCIENCES INC | US03969F1093 |
| Coherus BioSciences | US19249H1032 |
| SORRENTO Therapeutics Inc. | US83587F2020 |
| PLURISTEM THERAPEUTICS Inc. | US72940R3003 |
| IDEAYA Biosciences Inc. | US45166A1025 |
| Castle Biotechnologies Inc. | US14843C1053 |
| Unternehmen Codexis Inc. | US1920051067 |
| Arvinas Inc. | US04335A1051 |
| 10X Genomics Inc | US88025U1097 |
| Beam Therapeutics Inc. | US07373V1052 |
| BIONANO GENOMICS INC | US09075F1075 |
| Personalis Inc. | US71535D1063 |
| Precision Biosciences Inc. | US74019P1084 |
| Invitae Corp. | US46185L1035 |
| uniQure B.V. | NL0010696654 |
| Aqua Bounty Technologies Inc. | US03842K2006 |
| Cerner Corp. | US1567821046 |
| Moderna Inc. | US60770K1079 |
| Intellia Therapeutics Inc. | US45826J1051 |
| CRISPR Therapeutics AG | CH0334081137 |
| Editas Medicine Inc. | US28106W1036 |
| Novocure Ltd. | JE00BYSS4X48 |
| Sangamo BioSciences Inc. | US8006771062 |
| Quest Diagnostics | US74834L1008 |
| ICU Medical | US44930G1076 |
| Biomarin Pharmaceutical Inc. | US09061G1013 |
| Seagen Inc | US81181C1045 |
| Incyte Corp. Ltd. | US45337C1027 |
| Icon Plc. | IE0005711209 |
| BioTelemetry Inc. | US0906721065 |
| Neurocrine Biosciences Inc. | US64125C1099 |
| Schrodinger Inc. | US80810D1037 |
SVSP Kategorie
| SVSP Code | 1300 |
| Typ | Tracker-Zertifikate |
| SVSP Kategorie Code | 13 |
| SVSP Kategorie Name | Partizipationsprodukte |
Management
| Aktiv gemanagt | Ja |
Quelle: dp Derivative Partners